Dr. Mates said: "Medincell is entering a new era and I’m excited to help shape its future. Its vision and achievements closely align with my passion for advancing medical innova ...

Galderma is a pure-play dermatology company, with a leadership position in the self-care segment of the market, with more than 90% of total sales paid by consumers out of pocket. Its long-term revenue ...

NeuroScientific Biopharmaceuticals has made a second heavy-hitting appointment, with Melbourne-based exec Nathan Smith ...

Last week, a US Food and Drug Administration (FDA) advisory committee (AdCom) voted against approval of Danish drugmaker ...

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including Sanofi's $1.6B acquisition ...

Pakistan’s pharmaceutical sector stands as one of the steadily growing industries within the country’s economy.

The second quarter of 2025 was a period of dynamic evolution within the biotech and pharma sectors. Critical factors like ...

Detailed price information for Thermo Fisher Scientific Inc (TMO-N) from The Globe and Mail including charting and trades.

Sanofi's wide lineup of branded drugs and vaccines and robust pipeline create strong cash flows and a narrow economic moat. Growth of existing products and new product launches should help offset ...

Sanofi is paying up to US $1.6 billion for Vicebio, taking UQ’s Molecular Clamp vaccine tech global in Australia’s biggest university IP exit.

According to the terms of the agreement, Sanofi will acquire London-based Vicebio’s entire share capital for an upfront ...